Biopharma with its own CNS drugs (Lybalvi for schizophrenia) plus royalties from partnered long-acting drug-delivery technology.
Biopharma with its own CNS drugs (Lybalvi for schizophrenia) plus royalties from partnered long-acting drug-delivery technology.
Earns from two sources: its own medicines, sold to psychiatrists and addiction clinics by a US sales force, and royalties and manufacturing fees from partners whose long-acting injectable drugs rely on its technology, such as Johnson & Johnson's. Own-product sales are the larger share, and royalty income costs little to earn and helps fund the pipeline.
Moat: narrow (IP / patents, process know-how). Proprietary long-acting and combination drug-delivery technology underlies both its own drugs and partner royalties.
Headquarters: Dublin, Ireland · Founded: 1987 · Employees: 2,050
Size Alkermes Public (ALKS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.87B, the 887th largest of 3,085 United States companies the cockpit tracks. Shares closed at $46.85 on 18 Nov 2026.
Performance Over six months the shares gained 26.7%, against +4.4% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 15.3% over the last twelve months (peer median +13.3%); the operating margin is 5.3% (peer median 16.4%).
Valuation It trades at 5.0× enterprise value to sales against a peer median of 6.0× (9th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.8 points below its cost of capital (6.5% WACC).
Short interest Short interest is 11.7% of the free float (30 Oct 2026).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.75B | $1.48B | $1.56B | $1.66B | $1.11B |
| Revenue growth | — | -5% | -6% | +50% | — |
| Gross profit | $1.39B | $1.27B | $1.31B | $1.37B | $847M |
| EBITDA | $173M | $281M | $449M | $489M | $71.8M |
| Net income | -$351,000 | $242M | $367M | $356M | -$158M |
| Free cash flow | $227M | $480M | $406M | $353M | -$17.2M |
| Capital expenditure | $15.6M | $40.4M | $33.5M | $48.0M | $38.3M |
| Total debt | $1.57B | $70.0M | $75.5M | $372M | $379M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Alkermes Public ALKS | $7.87B | +27% | +15% | 5% | 5.0× | 32.5% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 6.9× | 3.7% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 3.6× | 10.5% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
| Supernus Pharmaceuticals SUPN | $6.02B | -41% | +16% | 45% | 4.5× | 6.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALKS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.2% | +1.7% | 9th highest of 21 |
| 6-month return | +26.7% | +4.4% | 5th highest of 21 |
| Distance from 52-week high | -15.8% | -10.8% | 10th lowest of 21 |
| Revenue growth (TTM) | +15.3% | +13.3% | 11th highest of 21 |
| Operating margin | 5.3% | 16.4% | 7th lowest of 20 |
| EV / Sales | 5.0× | 6.0× | 9th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 32.5% | 8.8% | most demanding of 13 |
| Growth delivered (Del g) | +7.3% | +9.3% | 4th lowest of 13 |
| Hurdle (Req g minus delivered) | +25.2 pp | -2.7 pp | most demanding of 13 |
| ROIC minus cost of capital | -3.8 pp | +1.9 pp | 5th lowest of 18 |
| EV / EBITDA | 50.1× | 18.9× | 3rd most expensive of 13 |
| Net debt / EBITDA | 4.7× | -0.3× | 2nd most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | 5.0× | 32.5% | +7.3% |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 7.4× | 7.3% | +12.6% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 4.7× | 27.3% | +9.4% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $7.74B | -15% | +10% | 6% | 2.2× | 19.9% | +5.8% |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 3.4× | 17.2% | +8.7% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.23B | 0% | +4% | 3% | 0.3× | -10.1% | +8.1% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | 29.0× | n/a | n/a |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 2.4× | 7.1% | +7.1% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 7.3× | 10.4% | +45.5% |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 13.6× | 17.5% | +10.0% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 7.3× | 23.9% | +16.6% |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 2.1× | -4.7% | +9.3% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 2.1× | -6.8% | +10.8% |
| Praxis Precision Medicines PRAX | United States | $8.53B | -9% | -100% | n/a | n/a | n/a | n/a |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $7.27B | +20% | +18% | 17% | 5.7× | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | 64.3× | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | 44.3× | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 8.6× | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | 12.9× | n/a | n/a |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $9.16B | +69% | +9% | 26% | 2.6× | -6.6% | +6.6% |
| Madrigal Pharmaceuticals MDGL | United States | $9.25B | -22% | +93% | -11% | 6.0× | n/a | n/a |